VJHemOnc is committed to improving our service to you

ASH 2019 | OAsIs trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed MCL

VJHemOnc is committed to improving our service to you

Simon Rule

Simon Rule, MD, Plymouth University, Plymouth, UK, discusses the OAsIs trial (NCT02558816), a multicenter, non-randomized, phase I study designed to assess the safety, tolerability, and efficacy of ibrutinib, venetoclax plus obinutuzumab in newly diagnosed mantle cell lymphoma (MCL). Prof. Rule reveals combination therapies may be relevant for the future, in order to improve outcomes whilst moving away from chemotherapy. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter